These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
270 related articles for article (PubMed ID: 38639185)
1. The role of ferroptosis in radiotherapy and combination therapy for head and neck squamous cell carcinoma (Review). Feng Y; Li X; Yang B; Li M; Du Y; Wang J; Liu S; Gong L; Li L; Gao L Oncol Rep; 2024 Jun; 51(6):. PubMed ID: 38639185 [TBL] [Abstract][Full Text] [Related]
2. Glutamine inhibition combined with CD47 blockade enhances radiotherapy-induced ferroptosis in head and neck squamous cell carcinoma. Song A; Wu L; Zhang BX; Yang QC; Liu YT; Li H; Mao L; Xiong D; Yu HJ; Sun ZJ Cancer Lett; 2024 Apr; 588():216727. PubMed ID: 38431035 [TBL] [Abstract][Full Text] [Related]
3. MitoTam induces ferroptosis and increases radiosensitivity in head and neck cancer cells. Reinema FV; Hudson N; Adema GJ; Peeters WJM; Neuzil J; Stursa J; Werner L; Sweep FCGJ; Bussink J; Span PN Radiother Oncol; 2024 Nov; 200():110503. PubMed ID: 39186982 [TBL] [Abstract][Full Text] [Related]
4. SENP1 inhibits ferroptosis and promotes head and neck squamous cell carcinoma by regulating ACSL4 protein stability via SUMO1. Xu X; Mao Y; Feng Z; Dai F; Gu T; Zheng J Oncol Rep; 2024 Feb; 51(2):. PubMed ID: 38186303 [TBL] [Abstract][Full Text] [Related]
5. EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation. Alsahafi EN; Thavaraj S; Sarvestani N; Novoplansky O; Elkabets M; Ayaz B; Tavassoli M; Legends MF Cancer Lett; 2021 Feb; 498():80-97. PubMed ID: 33137407 [TBL] [Abstract][Full Text] [Related]
6. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients. Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098 [TBL] [Abstract][Full Text] [Related]
7. Carbonyl reductase 1 is a new target to improve the effect of radiotherapy on head and neck squamous cell carcinoma. Yun M; Choi AJ; Lee YC; Kong M; Sung JY; Kim SS; Eun YG J Exp Clin Cancer Res; 2018 Oct; 37(1):264. PubMed ID: 30376862 [TBL] [Abstract][Full Text] [Related]
8. A genome-wide CRISPR screen reveals that antagonism of glutamine metabolism sensitizes head and neck squamous cell carcinoma to ferroptotic cell death. Allevato MM; Trinh S; Koshizuka K; Nachmanson D; Nguyen TC; Yokoyama Y; Wu X; Andres A; Wang Z; Watrous J; Molinolo AA; Mali P; Harismendy O; Jain M; Wild R; Gutkind JS Cancer Lett; 2024 Aug; 598():217089. PubMed ID: 38964731 [TBL] [Abstract][Full Text] [Related]
9. Tris(8-Hydroxyquinoline)iron induces apoptotic cell death via oxidative stress and by activating death receptor signaling pathway in human head and neck carcinoma cells. Chan LP; Tseng YP; Ding HY; Pan SM; Chiang FY; Wang LF; Chou TH; Lien PJ; Liu C; Kuo PL; Liang CH Phytomedicine; 2019 Oct; 63():153005. PubMed ID: 31302316 [TBL] [Abstract][Full Text] [Related]
10. Advances in the study of regulators of ferroptosis in head and neck squamous cell carcinoma (Review). Yang M; Guo R; Chen X; Song G; Zhang F Int J Mol Med; 2023 Jun; 51(6):. PubMed ID: 37052257 [TBL] [Abstract][Full Text] [Related]
11. Caveolin-1 promotes cancer progression via inhibiting ferroptosis in head and neck squamous cell carcinoma. Lu T; Zhang Z; Pan X; Zhang J; Wang X; Wang M; Li H; Yan M; Chen W J Oral Pathol Med; 2022 Jan; 51(1):52-62. PubMed ID: 34874578 [TBL] [Abstract][Full Text] [Related]
12. Ferroptosis Signature Shapes the Immune Profiles to Enhance the Response to Immune Checkpoint Inhibitors in Head and Neck Cancer. Chung CH; Lin CY; Chen CY; Hsueh CW; Chang YW; Wang CC; Chu PY; Tai SK; Yang MH Adv Sci (Weinh); 2023 May; 10(15):e2204514. PubMed ID: 37026630 [TBL] [Abstract][Full Text] [Related]
13. Role of Vitamin D in Head and Neck Cancer-Immune Function, Anti-Tumour Effect, and Its Impact on Patient Prognosis. Starska-Kowarska K Nutrients; 2023 May; 15(11):. PubMed ID: 37299554 [TBL] [Abstract][Full Text] [Related]
14. Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models. Frederick BA; Gupta R; Atilano-Roque A; Su TT; Raben D Radiat Res; 2020 Nov; 194(5):519-531. PubMed ID: 32936912 [TBL] [Abstract][Full Text] [Related]
15. PARP Inhibition Enhances Radiotherapy of SMAD4-Deficient Human Head and Neck Squamous Cell Carcinomas in Experimental Models. Hernandez AL; Young CD; Bian L; Weigel K; Nolan K; Frederick B; Han G; He G; Devon Trahan G; Rudolph MC; Jones KL; Oweida AJ; Karam SD; Raben D; Wang XJ Clin Cancer Res; 2020 Jun; 26(12):3058-3070. PubMed ID: 32139402 [TBL] [Abstract][Full Text] [Related]
16. Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions. Rothschild U; Muller L; Lechner A; Schlösser HA; Beutner D; Läubli H; Zippelius A; Rothschild SI Swiss Med Wkly; 2018; 148():w14625. PubMed ID: 29756633 [TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer. Cripps C; Winquist E; Devries MC; Stys-Norman D; Gilbert R; Curr Oncol; 2010 Jun; 17(3):37-48. PubMed ID: 20567625 [TBL] [Abstract][Full Text] [Related]
18. Integration of molecular targeted therapy with radiation in head and neck cancer. Du Y; Peyser ND; Grandis JR Pharmacol Ther; 2014 Apr; 142(1):88-98. PubMed ID: 24280066 [TBL] [Abstract][Full Text] [Related]
19. Combination RSL3 Treatment Sensitizes Ferroptosis- and EGFR-Inhibition-Resistant HNSCCs to Cetuximab. Liu S; Yan S; Zhu J; Lu R; Kang C; Tang K; Zeng J; Ding M; Guo Z; Lai X; Jiang Y; Wu S; Zhou L; Sun L; Zhou ZW Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012290 [TBL] [Abstract][Full Text] [Related]
20. Evolving role of novel radiosensitizers and immune checkpoint inhibitors in (chemo)radiotherapy of locally advanced head and neck squamous cell carcinoma. Ngamphaiboon N; Chairoungdua A; Dajsakdipon T; Jiarpinitnun C Oral Oncol; 2023 Oct; 145():106520. PubMed ID: 37467684 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]